Goldman Sachs: BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 35.3 M | Venta |
4,233,277
-248,597
| -6% | -USD 2.34 M | ﹤0.01% | 2039 |
|
|
2026
Q2 | USD 44.8 M | Compra |
4,481,874
+2,134,431
| +91% | +USD 19.3 M | ﹤0.01% | 1906 |
|
|
2026
Q1 | USD 22.3 M | Venta |
2,347,443
-865,342
| -27% | -USD 6.72 M | ﹤0.01% | 2331 |
|
|
2025
Q4 | USD 25.1 M | Compra |
3,212,785
+500,979
| +18% | +USD 3.62 M | ﹤0.01% | 2159 |
|
|
2025
Q3 | USD 20.6 M | Venta |
2,711,806
-812,111
| -23% | -USD 6.76 M | ﹤0.01% | 2244 |
|
|
2025
Q2 | USD 31.6 M | Compra |
3,523,917
+1,591,983
| +82% | +USD 14.8 M | ﹤0.01% | 1710 |
|
|
2025
Q1 | USD 14.5 M | Compra |
1,931,934
+640,704
| +50% | +USD 5.17 M | ﹤0.01% | 2336 |
|
|
2024
Q4 | USD 9.7 M | Venta |
1,291,230
-1,029,299
| -44% | -USD 7.81 M | ﹤0.01% | 2838 |
|
|
2024
Q3 | USD 17.6 M | Venta |
2,320,529
-209,730
| -8% | -USD 1.59 M | ﹤0.01% | 2181 |
|
|
2024
Q2 | USD 15.6 M | Compra |
2,530,259
+604,894
| +31% | +USD 3.34 M | ﹤0.01% | 2082 |
|
|
2024
Q1 | USD 9.8 M | Compra |
1,925,365
+150,611
| +8% | +USD 847 k | ﹤0.01% | 2468 |
|
|
2023
Q4 | USD 10.6 M | Compra |
1,774,754
+232,043
| +15% | +USD 1.34 M | ﹤0.01% | 2473 |
|
|
2023
Q3 | USD 10.9 M | Compra |
1,542,711
+63,922
| +4% | +USD 459 k | ﹤0.01% | 2312 |
|
|
2023
Q2 | USD 10.4 M | Compra |
1,478,789
+352,083
| +31% | +USD 2.83 M | ﹤0.01% | 2407 |
|
|
2023
Q1 | USD 9.4 M | Venta |
1,126,706
-4,988
| -0.4% | -USD 48 k | ﹤0.01% | 2481 |
|
|
2022
Q4 | USD 13 M | Venta |
1,131,694
-337,461
| -23% | -USD 4.21 M | ﹤0.01% | 2340 |
|
|
2022
Q3 | USD 18.5 M | Compra |
1,469,155
+92,443
| +7% | +USD 1.19 M | ﹤0.01% | 1940 |
|
|
2022
Q2 | USD 14.6 M | Compra |
1,376,712
+103,087
| +8% | +USD 1.06 M | ﹤0.01% | 2161 |
|
|
2022
Q1 | USD 20.7 M | Compra |
1,273,625
+459,965
| +57% | +USD 7.38 M | ﹤0.01% | 2023 |
|
|
2021
Q4 | USD 11.3 M | Compra |
813,660
+45,965
| +6% | +USD 608 k | ﹤0.01% | 2651 |
|
|
2021
Q3 | USD 11 M | Venta |
767,695
-42,467
| -5% | -USD 670 k | ﹤0.01% | 2625 |
|
|
2021
Q2 | USD 12.8 M | Venta |
810,162
-1,360,428
| -63% | -USD 18.5 M | ﹤0.01% | 2462 |
|
|
2021
Q1 | USD 22.1 M | Compra |
2,170,590
+1,866,955
| +615% | +USD 19.3 M | 0.01% | 1852 |
|
|
2020
Q4 | USD 2.26 M | Venta |
303,635
-1,166,305
| -79% | -USD 6.01 M | ﹤0.01% | 3639 |
|
|
2020
Q3 | USD 5.05 M | Venta |
1,469,940
-754,732
| -34% | -USD 3.23 M | ﹤0.01% | 2895 |
|
|
2020
Q2 | USD 10.6 M | Compra |
2,224,672
+760,132
| +52% | +USD 3.04 M | ﹤0.01% | 2225 |
|
|
2020
Q1 | USD 2.93 M | Compra |
1,464,540
+341,261
| +30% | +USD 940 k | ﹤0.01% | 3040 |
|
|
2019
Q4 | USD 3.88 M | Compra |
1,123,279
+80,648
| +8% | +USD 203 k | ﹤0.01% | 3161 |
|
|
2019
Q3 | USD 2.99 M | Compra |
1,042,631
+36,924
| +4% | +USD 115 k | ﹤0.01% | 3240 |
|
|
2019
Q2 | USD 3.81 M | Compra |
1,005,707
+622,093
| +162% | +USD 3.74 M | ﹤0.01% | 3047 |
|
|
2019
Q1 | USD 3.12 M | Compra |
383,614
+229,103
| +148% | +USD 1.96 M | ﹤0.01% | 3317 |
|
|
2018
Q4 | USD 1.25 M | Compra |
154,511
+10,043
| +7% | +USD 78.1 k | ﹤0.01% | 3844 |
|
|
2018
Q3 | USD 1.1 M | Compra |
144,468
+45,674
| +46% | +USD 307 k | ﹤0.01% | 3993 |
|
|
2018
Q2 | USD 566 k | Venta |
98,794
-1,615
| -2% | -USD 8.89 k | ﹤0.01% | 4436 |
|
|
2018
Q1 | USD 479 k | Venta |
100,409
-83,234
| -45% | -USD 428 k | ﹤0.01% | 4524 |
|
|
2017
Q4 | USD 901 k | Venta |
183,643
-177,294
| -49% | -USD 859 k | ﹤0.01% | 4402 |
|
|
2017
Q3 | USD 1.89 M | Venta |
360,937
-563,820
| -61% | -USD 2.89 M | ﹤0.01% | 4050 |
|
|
2017
Q2 | USD 5.14 M | Compra |
924,757
+137,068
| +17% | +USD 835 k | ﹤0.01% | 3029 |
|
|
2017
Q1 | USD 6.62 M | Compra |
787,689
+46,249
| +6% | +USD 322 k | ﹤0.01% | 2707 |
|
|
2016
Q4 | USD 4.69 M | Venta |
741,440
-155,302
| -17% | -USD 808 k | ﹤0.01% | 3108 |
|
|
2016
Q3 | USD 3.96 M | Venta |
896,742
-249,338
| -22% | -USD 996 k | ﹤0.01% | 3249 |
|
|
2016
Q2 | USD 3.26 M | Venta |
1,146,080
-91,338
| -7% | -USD 284 k | ﹤0.01% | 3206 |
|
|
2016
Q1 | USD 3.5 M | Compra |
1,237,418
+155,133
| +14% | +USD 688 k | ﹤0.01% | 2992 |
|
|
2015
Q4 | USD 11.2 M | Compra |
1,082,285
+52,515
| +5% | +USD 522 k | ﹤0.01% | 2170 |
|
|
2015
Q3 | USD 11.7 M | Venta |
1,029,770
-3,394
| -0.3% | -USD 45.3 k | ﹤0.01% | 2123 |
|
|
2015
Q2 | USD 15.4 M | Compra |
1,033,164
+596
| +0.1% | +USD 6.78 k | ﹤0.01% | 1999 |
|
|
2015
Q1 | USD 9.32 M | Compra |
1,032,568
+774,093
| +299% | +USD 8.01 M | ﹤0.01% | 2349 |
|
|
2014
Q4 | USD 3.14 M | Compra |
258,475
+223,158
| +632% | +USD 2.46 M | ﹤0.01% | 3410 |
|
|
2014
Q3 | USD 345 k | Compra |
35,317
+13,309
| +60% | +USD 163 k | ﹤0.01% | 5621 |
|
|
2014
Q2 | USD 281 k | Venta |
22,008
-4,333
| -16% | -USD 42.2 k | ﹤0.01% | 5908 |
|
|
2014
Q1 | USD 279 k | Venta |
26,341
-72,461
| -73% | -USD 773 k | ﹤0.01% | 5797 |
|
|
2013
Q4 | USD 751 k | Venta |
98,802
-86,139
| -47% | -USD 545 k | ﹤0.01% | 4984 |
|
|
2013
Q3 | USD 1.35 M | Venta |
184,941
-21,834
| -11% | -USD 111 k | ﹤0.01% | 4316 |
|
|
2013
Q2 | USD 321 k | Compra |
+206,775
| Nuevas | +USD 357 k | ﹤0.01% | 5279 |
|
Otros fondos que tienen BCRX en su portafolio
JHC
Posición de Goldman Sachs en BCRX: resumen de T3 2026
Goldman Sachs redujo su participación en BioCryst Pharmaceuticals (BCRX) en 5.5% durante T3 2026, al vender acciones por un valor estimado de USD 2.34 M y quedarse con 4,233,277 acciones valuadas en USD 35.3 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #2039.
Goldman Sachs reportó por primera vez una posición en BCRX en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 44.8 M en T2 2026. Al cierre de T3 2026, 334 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T3 2026, Goldman Sachs tenía 4,233,277 acciones de BioCryst Pharmaceuticals con un valor de USD 35.3 M.
- Goldman Sachs vendió 248,597 acciones de BioCryst Pharmaceuticals en T3 2026, por un valor estimado de USD 2.34 M.
- BioCryst Pharmaceuticals representó el ﹤0.01% del portafolio de Goldman Sachs en T3 2026 y fue su posición número 2039.
- Goldman Sachs reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de Goldman Sachs en BioCryst Pharmaceuticals alcanzó su máximo de USD 44.8 M en T2 2026.
- Al cierre de T3 2026, 334 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en su portafolio.
Según el informe 13F de Goldman Sachs correspondiente a T3 2026, presentado el 16 nov 2026.